US FDA Requests More Information, Needs More Time To Review Birth Control OTC Switch Proposal
Executive Summary
FDA decision on Perrigo subsidiary’s proposal for first US OTC daily oral contraceptive is extended 90 days with the postponement of an advisory panel meeting. Agency requested additional information related to OTC switch application of 0.075-mg norgestrel initially submitted in July.
You may also be interested in...
For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion
After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.
US Consumer Health Industry In 2023: Monograph Results, Switch Hopes On OTC Drug Sector Radar
OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight reports on OTC drug sector’s outlook for the FDA potentially publishing a final rule to expand switch opportunities as well as its anticipation of marketplace results from monograph program overhaul.
20 Democrat, 1 GOP State AGs Frame OTC Birth Control Within Protecting Reproductive Rights
Citing national uncertainty regarding reproductive health care – “ a time when reproductive rights have been curtailed across the country – state AGs urge FDA to approve OTC birth control proposal from HRA Pharma.